# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Mike Matson reiterates Conmed (NYSE:CNMD) with a Buy and maintains $107 price target.
JP Morgan analyst Robbie Marcus maintains Conmed (NYSE:CNMD) with a Overweight and lowers the price target from $115 to $75.
Wells Fargo analyst Vik Chopra maintains Conmed (NYSE:CNMD) with a Equal-Weight and lowers the price target from $98 to $77.
Piper Sandler analyst Matt O'Brien maintains Conmed (NYSE:CNMD) with a Overweight and lowers the price target from $100 ...
Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $129 to $107.
CONMED Corporation (NYSE:CNMD) today announced that Patrick Beyer, President of International and Global Orthopedics, has been ...